TECH - Bio-Techne Corporation
Antwerp, May 21, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (“ CMBT ”, “ CMB.TECH ” or “the c ompany”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs : CMBTO) announces that today the General Meeting of Shareholders has approved the annual accounts for the year ended 31 December 202 5 . All other resolutions proposed by CMB.TECH's Supervisory Board were also approved. Re appointment of Supervisory Board members for a period of three years
CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript
CMB.TECH NYSE: CMBT reported a strong first quarter of 2026, with management highlighting higher revenue, reduced leverage, lower financing costs and substantial gains from vessel sales during an earnings call titled “Firing on All Cylinders.”
CMB.TECH ANNOUNCES Q1 2026 RESULTS FIRING ON ALL CYLINDERS ANTWERP, Belgium, 19 May 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the first quarter ended 31 March 2026. HIGHLIGHTS Financial highlights: Profit for the period of USD 368.8 million in Q1 2026.
Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ANTWERP, Belgium, 7 May 2026 – CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2026 earnings prior to market opening on Tuesday 19 May 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.
Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript
Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.
Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago.
Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026.
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026. Third Quarter FY2026 Highlights Reported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipments GAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56 Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growth Growth vectors performed well, with mid‑single‑digit growth in Proteomic Analysis instruments, mid‑teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast‑track customers "The Bio‑Techne team delivered solid execution amid a mixed end‑market environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.
MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.
ANTWERP, Belgium, 21 April 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) published its annual report in accordance with Belgian law and submits Form 20-F for the year ended on 31 December 2025. CMB.TECH further invites its shareholders to participate in the Annual General Meeting and the Special General Meeting that will be held on Thursday 21 May 2026.
Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy
Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Biogen Inc. (BIIB) and Techne (TECH). But which of these two stocks is more attractive to value investors?
MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 financial results.
Techne (TECH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.